BMO reiterates Outperform on National Health Investors stock
BMO Capital reiterated an Outperform rating and $80.00 price target on National Health Investors (NHI). The company, trading near its 52-week low, focuses on growth through acquisitions and its SHOP portfolio. NHI reported Q2 2026 earnings beating profit expectations but missing revenue forecasts, with a dividend increase and asset sale gains. Truist Securities lowered its price target to $80, maintaining a Buy rating.
How this was made
The 30-second read
Why it matters
Analyst upgrades and dividend increase reinforce a bullish short-term outlook.
Market read
Earnings beat and dividend hike provide actionable insight for traders in the REIT space.
What to watch
Potential headwinds from CFO transition and deferred tax expenses could affect future performance.
Background
BMO Capital reiterates Outperform on NHI with $80 price target; Truist lowers target to $80.
Ticker impact
Q2 2026 earnings beat EPS estimate and dividend increase; sale of NHC portfolio for $560M disclosed.
Potential modest price rise ahead of next trading session.
Earnings beat, dividend raise, and large portfolio sale provide fresh, material information for investors.
Market effects
May boost sentiment in REIT and senior housing sectors.
Limited to U.S. REIT market.
Low
Counterpoint
The earnings beat may be offset by lower-than-expected revenue and compressing acquisition yields.
Key entities
- companyNational Health Investors
REIT focused on senior housing and health care properties.
- analystBMO Capital
Maintains Outperform rating and $80 price target.



